Recurrent Glioblastoma Treatment: D2C7-ATC Shows Early Promise in Phase 1 Trial
Recurrent glioblastoma treatment research is exploring D2C7-ATC, an experimental therapy targeting EGFR and EGFRvIII through direct delivery into the tumour. This patient-focused review explains the Phase 1 survival and safety findings, exploratory biomarkers, study limitations and essential questions families should discuss with a specialist neuro-oncology team.